Literature DB >> 26770291

The Worldwide Economic Impact of Neurogenic Bladder.

Chandra Flack1, C R Powell1.   

Abstract

Costs of neurogenic bladder vary widely and depend on a number of factors including severity of disease, symptomatology, patient insurance, and devices required. Recognition of how each treatment strategy will impact the patient financially could help guide selection of treatment as well as improve compliance with the chosen regimen. We have attempted to provide an overview of long term cost considerations for the neurogenic bladder patient. Armed with this information, the practitioner can better help the patient select a bladder care regimen that balances the desire to both minimize symptoms now and preserve urinary tract integrity for the future, yet still remain cost effective.

Entities:  

Keywords:  Costs and cost analysis; Health expenditures; Incontinence pads; Intermittent urethral catheterization; Urinary bladder - neurogenic; Urinary bladder - overactive; Urinary incontinence; Urinary retention

Year:  2015        PMID: 26770291      PMCID: PMC4707967          DOI: 10.1007/s11884-015-0323-6

Source DB:  PubMed          Journal:  Curr Bladder Dysfunct Rep        ISSN: 1931-7212


  24 in total

1.  The current and future burden and cost of overactive bladder in five European countries.

Authors:  Penny Reeves; Deb Irwin; Con Kelleher; Ian Milsom; Zoe Kopp; Neill Calvert; Adam Lloyd
Journal:  Eur Urol       Date:  2006-05-09       Impact factor: 20.096

Review 2.  The neurogenic bladder: an update with management strategies for primary care physicians.

Authors:  Adam P Klausner; William D Steers
Journal:  Med Clin North Am       Date:  2011-01       Impact factor: 5.456

Review 3.  Current evidence on intermittent catheterization: sterile single-use catheters or clean reused catheters and the incidence of UTI.

Authors:  Kathryn Getliffe; Mandy Fader; Colleen Allen; Kim Pinar; Katherine N Moore
Journal:  J Wound Ostomy Continence Nurs       Date:  2007 May-Jun       Impact factor: 1.741

4.  Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.

Authors:  Nazema Y Siddiqui; Cindy L Amundsen; Anthony G Visco; Evan R Myers; Jennifer M Wu
Journal:  J Urol       Date:  2009-10-17       Impact factor: 7.450

Review 5.  Economic burden of urgency urinary incontinence in the United States: a systematic review.

Authors:  Karin S Coyne; Alan Wein; Sean Nicholson; Marion Kvasz; Chieh-I Chen; Ian Milsom
Journal:  J Manag Care Pharm       Date:  2014-02

Review 6.  Complications of intermittent catheterization: their prevention and treatment.

Authors:  J J Wyndaele
Journal:  Spinal Cord       Date:  2002-10       Impact factor: 2.772

7.  EAU guidelines on neurogenic lower urinary tract dysfunction.

Authors:  Manfred Stöhrer; Bertil Blok; David Castro-Diaz; Emanuel Chartier-Kastler; Giulio Del Popolo; Guus Kramer; Jürgen Pannek; Piotr Radziszewski; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2009-04-21       Impact factor: 20.096

8.  Bladder cancer in patients with spinal cord injury.

Authors:  Marika J Hess; Ellen H Zhan; Dominic K Foo; Subbarao V Yalla
Journal:  J Spinal Cord Med       Date:  2003       Impact factor: 1.985

Review 9.  Intermittent catheterisation for long-term bladder management.

Authors:  Jacqui Prieto; Catherine L Murphy; Katherine N Moore; Mandy Fader
Journal:  Cochrane Database Syst Rev       Date:  2014-09-10

Review 10.  Neurogenic bladder in spinal cord injury patients.

Authors:  Waleed Al Taweel; Raouf Seyam
Journal:  Res Rep Urol       Date:  2015-06-10
View more
  2 in total

1.  Establishing a core outcome set for neurogenic bladder trials: study protocol for a scoping review and Delphi surveys.

Authors:  Yan Zhang; Yamin Chen; Mingming Niu; Yuanyuan Li; Jiaoyan Zhang; Li Zhang; Fangfang Wu; Qingyun Chen; Huijin Yu; Jinhui Tian
Journal:  Trials       Date:  2022-06-13       Impact factor: 2.728

2.  A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapy.

Authors:  Sarah L Hecht; Alan Quach; Dexiang Gao; Andrew Brazell; Gemma Beltran; Sheryl Holbrook; Lia Gore; Nao Iguchi; Anna Malykhina; Duncan Wilcox; Nicholas G Cost
Journal:  Pediatr Blood Cancer       Date:  2021-07-10       Impact factor: 3.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.